Bristol Myers Squibb (BMY)

Bristol-Myers Squibb's earnings more than doubled last quarter while its price sits roughly in the middle of its recent range.

What is going on right now?

The stock is trading around $61.48, slightly above where it averaged over the past few weeks but still below where it sat a month ago. Trading activity has been quieter than usual, with volume at about 60% of its norm.

How is the business itself doing?

This is a large drugmaker whose biggest sellers are cancer treatments like Opdivo and Yervoy. Revenue grew about 6% recently, and profit jumped roughly two and a half times. It keeps about 72 cents of every dollar after manufacturing costs.

What stands out?

The company carries debt equal to about twice what it owns outright, which is a lot. That said, it generates around $8 billion a year in cash, and its profit margins sit at 34%, so it has steady income to service that debt.

What comes next?

Its next earnings report is due October 29, the first chance to see whether the cancer drug lineup kept growing at this pace.